Pten as a prognostic/predictive biomarker in cancer: An unfulfilled promise?

Chiara Bazzichetto, Fabiana Conciatori, Matteo Pallocca, Italia Falcone, Maurizio Fanciulli, Francesco Cognetti, Michele Milella, Ludovica Ciuffreda

Research output: Contribution to journalArticle

Abstract

Identifying putative biomarkers of clinical outcomes in cancer is crucial for successful enrichment, and for the selection of patients who are the most likely to benefit from a specific therapeutic approach. Indeed, current research in personalized cancer therapy focuses on the possibility of identifying biomarkers that predict prognosis, sensitivity or resistance to therapies. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene that regulates several crucial cell functions such as proliferation, survival, genomic stability and cell motility through both enzymatic and non-enzymatic activities and phosphatidylinositol 3-kinase (PI3K)-dependent and -independent mechanisms. Despite its undisputed role as a tumor suppressor, assessment of PTEN status in sporadic human tumors has yet to provide clinically robust prognostic, predictive or therapeutic information. This is possibly due to the exceptionally complex regulation of PTEN function, which involves genetic, transcriptional, post-transcriptional and post-translational events. This review shows a brief summary of the regulation and function of PTEN and discusses its controversial aspects as a prognostic/predictive biomarker

Original languageEnglish
Article number435
JournalCancers
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 2019

    Fingerprint

Keywords

  • Biomarkers
  • Personalized cancer therapy
  • PTEN

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this